JP7752424B2 - シリアルキラーｔ細胞集団のインビトロ活性化及び拡大、ならびに腫瘍細胞殺傷細胞を有するがん患者の受動免疫化のための組成物及び方法 - Google Patents

シリアルキラーｔ細胞集団のインビトロ活性化及び拡大、ならびに腫瘍細胞殺傷細胞を有するがん患者の受動免疫化のための組成物及び方法

Info

Publication number
JP7752424B2
JP7752424B2 JP2022524134A JP2022524134A JP7752424B2 JP 7752424 B2 JP7752424 B2 JP 7752424B2 JP 2022524134 A JP2022524134 A JP 2022524134A JP 2022524134 A JP2022524134 A JP 2022524134A JP 7752424 B2 JP7752424 B2 JP 7752424B2
Authority
JP
Japan
Prior art keywords
cells
cell
population
tumor
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022524134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553411A5 (https=
JP2022553411A (ja
Inventor
フランク ボリエッロ
Original Assignee
アロプレックス バイオセラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/660,442 external-priority patent/US10731128B2/en
Application filed by アロプレックス バイオセラピューティクス filed Critical アロプレックス バイオセラピューティクス
Publication of JP2022553411A publication Critical patent/JP2022553411A/ja
Publication of JP2022553411A5 publication Critical patent/JP2022553411A5/ja
Application granted granted Critical
Publication of JP7752424B2 publication Critical patent/JP7752424B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022524134A 2019-10-22 2020-10-21 シリアルキラーｔ細胞集団のインビトロ活性化及び拡大、ならびに腫瘍細胞殺傷細胞を有するがん患者の受動免疫化のための組成物及び方法 Active JP7752424B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/660,442 2019-10-22
US16/660,442 US10731128B2 (en) 2016-11-22 2019-10-22 Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
PCT/US2020/056698 WO2021081115A1 (en) 2019-10-22 2020-10-21 Compositions and methods for in vitro activation and expansion of serial killer t cell populations and passive immunization of a cancer patient with tumor cell killing cells

Publications (3)

Publication Number Publication Date
JP2022553411A JP2022553411A (ja) 2022-12-22
JP2022553411A5 JP2022553411A5 (https=) 2023-10-24
JP7752424B2 true JP7752424B2 (ja) 2025-10-10

Family

ID=75619361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524134A Active JP7752424B2 (ja) 2019-10-22 2020-10-21 シリアルキラーｔ細胞集団のインビトロ活性化及び拡大、ならびに腫瘍細胞殺傷細胞を有するがん患者の受動免疫化のための組成物及び方法

Country Status (8)

Country Link
EP (1) EP4048291A4 (https=)
JP (1) JP7752424B2 (https=)
KR (1) KR20220103928A (https=)
AU (1) AU2020371619A1 (https=)
CA (1) CA3154876A1 (https=)
IL (1) IL292355A (https=)
MX (1) MX2022004772A (https=)
WO (1) WO2021081115A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113403274B (zh) * 2021-06-28 2023-11-10 上海睿臻迈生物医疗科技有限公司 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
WO2024221005A2 (en) * 2023-04-21 2024-10-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for inhibiting resistance to immune blockade inhibitor therapy
CN116970562B (zh) * 2023-09-22 2024-01-02 北京翊博生物集团有限公司 一种抗原特异性t细胞的制备方法及其在免疫治疗中的应用
CN119320750A (zh) * 2024-10-15 2025-01-17 南开大学 Tnfsf15蛋白在制备促进肥大细胞激活的产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004201A1 (en) 2009-07-10 2011-01-13 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
WO2018098279A1 (en) 2016-11-22 2018-05-31 Alloplex Biotherapeutics Allogenic tumor cell vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231204A1 (en) * 2000-01-27 2001-08-07 Sidney Kimmel Cancer Center Genetically engineered tumor cell vaccines
US7087225B2 (en) * 2001-08-16 2006-08-08 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
US20180267024A1 (en) * 2015-06-08 2018-09-20 Lophius Biosciences Gmbh Composition for determination of cell-mediated immune responsiveness
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004201A1 (en) 2009-07-10 2011-01-13 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
WO2018098279A1 (en) 2016-11-22 2018-05-31 Alloplex Biotherapeutics Allogenic tumor cell vaccine

Also Published As

Publication number Publication date
CA3154876A1 (en) 2021-04-29
EP4048291A1 (en) 2022-08-31
JP2022553411A (ja) 2022-12-22
MX2022004772A (es) 2022-07-19
IL292355A (en) 2022-06-01
AU2020371619A1 (en) 2022-05-12
KR20220103928A (ko) 2022-07-25
WO2021081115A1 (en) 2021-04-29
EP4048291A4 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
US10731128B2 (en) Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
JP7752424B2 (ja) シリアルキラーｔ細胞集団のインビトロ活性化及び拡大、ならびに腫瘍細胞殺傷細胞を有するがん患者の受動免疫化のための組成物及び方法
US12403186B2 (en) Allogeneic tumor cell vaccine
De Keersmaecker et al. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
JP2022091750A (ja) 細胞に基づくネオ抗原ワクチンおよびその使用
BR112021003305A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
TW202134264A (zh) 嵌合抗原受體及其用途
CN115175934A (zh) 靶向共有新抗原的抗原结合蛋白
US11185586B2 (en) Allogeneic tumor cell vaccine
JP2025163127A (ja) 同種異系腫瘍細胞ワクチン
US11951128B2 (en) Compositions and methods for the isolation and/or generation of specific CD4+ and CD8+ T-cell subsets
TW202140790A (zh) 病毒載體轉導細胞的方法
KR20260016919A (ko) 제시된 hpv16-, mart1-, cmv-, ebv-, 또는 인플루엔자-펩티드에 결합하는 t 세포 수용체
RU2822196C2 (ru) Способы получения клеток, экспрессирующих химерный антигенный рецептор
Paszkiewicz Development of a truncated EGFR marker as a safeguard for adoptive T cell therapy
Kandage Modulating anti-tumour-specific CD8+ cytotoxic T lymphocyte responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250922

R150 Certificate of patent or registration of utility model

Ref document number: 7752424

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150